Recent

% | $
Quotes you view appear here for quick access.

Oncolytics Biotech Inc. Message Board

  • alrisu alrisu Nov 16, 2012 4:14 PM Flag

    The experts

    Brian Klein, Stifel Nicolaus (11/9/12) "We continue to forecast positive results from Oncolytics Biotech Inc.'s randomized phase 2 trial of Reolysin in advanced head and neck cancer bin Q1/13. . .we believe positive results will significantly derisk the development program. . .we anticipate the randomized phase 2 trials in metastatic pancreatic cancer and metastatic ovarian cancer, being conducted by the National Cancer Institute, will yield top-line results in mid-2013. . .given the implication that Reolysin may be more suitable to metastatic disease, we anticipate these trials, which only include metastatic patients, will demonstrate compelling improvements on disease progression and could lead to additional pivotal trials."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • We said ballchinian. Well said

    • Alan Ridgeway, Paradigm Capital (11/12/12) "Positive data was presented from two clinical trials involving Oncolytics Biotech Inc.'s Reolysin on Nov. 9 at the 24th annual AACR-NIH-EORTC scientific conference in Dublin, Ireland. . .we believe the data presented supports our investment thesis for Oncolytics, which is based on our belief that Reolysin has the opportunity to be a transformational cancer therapeutic with the potential to be used to treat a broad number of cancers. . .we continue to believe the risk/reward opportunity related to an investment in Oncolytics at current levels is attractive."

      • 2 Replies to alrisu
      • For those like bridger48 and the other "et tu D2" posters, the analysts seem to vehemently disagree with you ..... as witnessed by the for-profit analysis of Alan Ridgeway and Brian Klein, who respectively has state that "Reolysin has the opportunity to be a transformational cancer therapeutic with the potential to be used to treat a broad number of cancer." and that "trials in metastatic pancreatic cancer and metastatic ovarian cancer, being conducted by the National Cancer Institute, will yield top-line results in mid-2013. "

        Brian Klein, Stifel Nicolaus (11/9/12) "We continue to forecast positive results from Oncolytics Biotech Inc.'s randomized phase 2 trial of Reolysin in advanced head and neck cancer bin Q1/13. . .we believe positive results will significantly derisk the development program. . .we anticipate the randomized phase 2 trials in metastatic pancreatic cancer and metastatic ovarian cancer, being conducted by the National Cancer Institute, will yield top-line results in mid-2013. . .given the implication that Reolysin may be more suitable to metastatic disease, we anticipate these trials, which only include metastatic patients, will demonstrate compelling improvements on disease progression and could lead to additional pivotal trials."

      • It's kind of jarring to hear analysts referred to as "experts", rather than the scientists whose data they are commenting on.

        Sentiment: Strong Buy

 
ONCY
0.6905+0.0005(+0.07%)Jun 2 3:59 PMEDT